|
OS
|
Gender (male vs. female)
|
0.334
|
0.62
|
0.24–1.63
|
|
Age (≤ 50 vs. > 50 years)
|
0.175
|
1.63
|
0.80–3.30
|
|
Pretreatment EBV DNA (< 4000 vs. ≥ 4000 copies/mL)
|
0.766
|
1.12
|
0.54–2.29
|
|
T stage (T1–2 vs. T3–4)
|
0.393
|
1.54
|
0.57–4.12
|
|
N stage (N0–1 vs. N2–3)
|
0.022
|
2.26
|
1.12–4.53
|
|
Clinical stage (II–III vs. IV)
|
0.134
|
1.86
|
0.83–4.18
|
|
Concurrent chemotherapy (docetaxel vs. cisplatin)
|
0.802
|
0.92
|
0.46–1.83
|
|
DMFS
|
Gender (male vs. female)
|
0.885
|
0.95
|
0.48–1.88
|
|
Age (≤ 50 vs. > 50 years)
|
0.901
|
0.96
|
0.52–1.79
|
|
Pretreatment EBV DNA (< 4000 vs. ≥ 4000 copies/mL)
|
0.039
|
1.85
|
1.030–3.31
|
|
T stage (T1–2 vs. T3–4)
|
0.600
|
1.22
|
0.59–2.51
|
|
N stage (N0–1 vs. N2–3)
|
0.017
|
2.01
|
1.14–3.58
|
|
Clinical stage (II–III vs. IV)
|
0.530
|
1.27
|
0.61–2.64
|
|
Concurrent chemotherapy (docetaxel vs. cisplatin)
|
0.827
|
1.07
|
0.60–1.88
|
|
LRFS
|
Gender (male vs. female)
|
0.146
|
1.85
|
0.81–4.21
|
|
Age (≤ 50 vs. ≥ 50 years)
|
0.986
|
0.99
|
0.41–2.42
|
|
Pretreatment EBV DNA (< 4000 vs. ≥ 4000 copies/mL)
|
0.852
|
0.92
|
0.39–2.17
|
|
T stage (T1–2 vs. T3–4)
|
0.418
|
1.58
|
0.52–4.79
|
|
N stage (N0–1 vs. N2–3)
|
0.128
|
1.86
|
0.84–4.13
|
|
Clinical stage (II–III vs. IV)
|
0.278
|
0.65
|
0.29–1.45
|
|
Concurrent chemotherapy (docetaxel vs. cisplatin)
|
0.288
|
0.65
|
0.29–1.45
|
|
NRFS
|
Gender (male vs. female)
|
0.337
|
0.55
|
0.16–1.88
|
|
Age (≤ 50 vs. > 50 years)
|
0.146
|
0.40
|
0.12–1.38
|
|
Pretreatment EBV DNA (< 4000 vs. ≥ 4000 copies/mL)
|
0.171
|
1.86
|
0.77–4.52
|
|
T stage (T1–2 vs. T3–4)
|
0.491
|
0.72
|
0.28–1.86
|
|
N stage (N0–1 vs. N2–3)
|
0.334
|
1.55
|
0.64–3.77
|
|
Clinical stage (II–III vs. IV)
|
0.783
|
0.81
|
0.18–3.71
|
|
Concurrent chemotherapy (docetaxel vs. cisplatin)
|
0.036
|
0.34
|
0.12–0.93
|
